Press Releases
Press Releases
-
AntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory Board
-
AntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors
-
AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101
-
AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month
-
AntriaBio Files Investigational New Drug Application for Once-Weekly Basal Insulin AB101
-
AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101
-
AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors
-
AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock
-
AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea
-
AntriaBio Announces $12 Million Private Placement
